SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-18-018511
Filing Date
2018-08-01
Accepted
2018-08-01 16:59:16
Documents
4
Period of Report
2018-07-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-8k_20180730.htm 8-K 32992
2 EX-5.1 kalv-ex51_6.htm EX-5.1 22602
3 EX-10.1 kalv-ex101_7.htm EX-10.1 81349
4 GRAPHIC gtvnpyfffzxk000001.jpg GRAPHIC 53041
  Complete submission text file 0001564590-18-018511.txt   211604
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 18985512
SIC: 2834 Pharmaceutical Preparations